Does Emgality Work for Migraines?
Emgality (galcanezumab) is FDA-approved to prevent migraines in adults, targeting calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks. Clinical trials showed it reduces monthly migraine days by 4-5 days on average compared to placebo after one month of 240 mg loading dose followed by 120 mg monthly injections.[1][2]
How Effective Is It in Studies?
In two pivotal trials (EVOLVE-1 and EVOLVE-2), 50% of patients on Emgality had at least 50% fewer migraine days versus 31% on placebo. A third trial (EVOLVE-301) confirmed benefits for cluster headaches, but migraines were the primary focus. Real-world data aligns, with many patients reporting 40-60% reduction in attack frequency.[1][3]
Who Responds Best and How Long to See Results?
It works for episodic (4-14 days/month) and chronic migraines (15+ days/month). About 60-70% of users see meaningful relief by month 3; non-responders often stop by then. Factors like prior CGRP failures or medication overuse predict poorer response.[2][4]
Common Side Effects and Risks
Injection-site reactions occur in 18% of users, mostly mild. Serious risks like allergic reactions or hypertension are rare (under 1%). No increased cardiovascular events in trials, but monitor blood pressure.[1][5]
How Does It Compare to Aimovig or Nurtec?
| Drug | Target | Dosing | Avg. Migraine Day Reduction | Cost (Monthly, Approx.) |
|------|--------|--------|-----------------------------|--------------------------|
| Emgality | CGRP monoclonal antibody | Monthly subQ | 4-5 days | $700-900 |
| Aimovig (erenumab) | CGRP receptor blocker | Monthly subQ | 3-4 days | $700-900 |
| Nurtec (rimegepant) | CGRP antagonist | As needed oral | Acute relief; 2-3 fewer days preventive | $800-1,000 |
Emgality edges out in head-to-heads for some chronic migraine patients, but choice depends on side effects and insurance.[3][6]
When Does the Patent Expire?
Core patents expire around 2030-2033, with some formulation patents to 2038. No biosimilars approved yet; challenges from Amgen competitors ongoing.[7]
Patient Experiences and When It Might Not Work
Many report life-changing relief from debilitating attacks, but 20-30% see minimal benefit, especially with aura-heavy or tension-migraines. Consult a neurologist for trials; combine with lifestyle changes for best results.[4][8]
[1]: FDA Label for Emgality
[2]: NEJM: EVOLVE-1/2 Trials
[3]: American Headache Society Guidelines
[4]: JAMA Neurology Real-World Study
[5]: Emgality Safety Data
[6]: Head-to-Head Comparison
[7]: DrugPatentWatch: Emgality Patents
[8]: Migraine.com Patient Forums